Shares of Sensus Healthcare Inc (NASDAQ:SRTS) have been given an average rating of “Buy” by the nine analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $10.63.
Several equities analysts have recently issued reports on the stock. Roth Capital reiterated a “buy” rating on shares of Sensus Healthcare in a report on Tuesday, February 19th. TheStreet upgraded shares of Sensus Healthcare from a “d” rating to a “c” rating in a report on Thursday, February 14th. Northland Securities reiterated a “sell” rating and set a $5.00 target price on shares of Sensus Healthcare in a report on Friday, February 15th. ValuEngine upgraded shares of Sensus Healthcare from a “hold” rating to a “buy” rating in a report on Wednesday, January 2nd. Finally, Craig Hallum assumed coverage on shares of Sensus Healthcare in a report on Tuesday, December 11th. They set a “buy” rating and a $10.00 target price for the company.
SRTS traded down $0.20 on Friday, hitting $7.50. The company had a trading volume of 1,094 shares, compared to its average volume of 59,282. Sensus Healthcare has a 52-week low of $5.00 and a 52-week high of $9.23. The firm has a market capitalization of $126.85 million, a PE ratio of -54.21 and a beta of -0.44.
Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, February 14th. The company reported $0.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.03. Sensus Healthcare had a negative net margin of 7.65% and a negative return on equity of 10.86%. The business had revenue of $8.08 million during the quarter, compared to analyst estimates of $7.33 million. Analysts anticipate that Sensus Healthcare will post 0.02 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. B. Riley Financial Inc. bought a new stake in shares of Sensus Healthcare during the third quarter valued at approximately $168,000. AWM Investment Company Inc. increased its position in shares of Sensus Healthcare by 34.6% during the third quarter. AWM Investment Company Inc. now owns 661,938 shares of the company’s stock valued at $5,547,000 after acquiring an additional 170,000 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Sensus Healthcare during the second quarter valued at approximately $164,000. Vanguard Group Inc increased its position in shares of Sensus Healthcare by 48.2% during the third quarter. Vanguard Group Inc now owns 305,833 shares of the company’s stock valued at $2,563,000 after acquiring an additional 99,444 shares in the last quarter. Finally, Stonepine Capital Management LLC bought a new stake in shares of Sensus Healthcare during the third quarter valued at approximately $317,000. 6.70% of the stock is owned by institutional investors.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Story: Blockchain
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.